Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Detoxification for triazolam physical dependence.

J T Sullivan1, E M Sellers

  • 1Clinical Research and Treatment Institute, Addiction Research Foundation, Toronto, Canada.

Journal of Clinical Psychopharmacology
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using observations and source specific model tracers to characterize pollutant transport during FRAPPÉ and DISCOVER-AQ.

Journal of geophysical research. Atmospheres : JGR·2020
Same author

Adding diagnostic power to the physical exam: can employing focused cardiac ultrasound lead to improved obstetric outcomes?

International journal of obstetric anesthesia·2018
Same author

Psilocybin: Good Trip or Bad Trip.

Clinical pharmacology and therapeutics·2017
Same author

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.

The Journal of pharmacology and experimental therapeutics·2016
Same author

Deconstructing Designer Drugs.

Clinical pharmacology and therapeutics·2016
Same author

The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Clinical pharmacology and therapeutics·2016
Same journal

Are the 8 Finnish Deaths Explained by Agranulocytosis More Important than the Thousands of Suicide Deaths Associated with the Lack of Use of Clozapine? Reflections on Clozaphobia.

Journal of clinical psychopharmacology·2026
Same journal

Aripiprazole Withdrawal-Associated Restless Legs Syndrome During Clozapine Treatment in an Adolescent With Schizoaffective Disorder: A Case Report.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Article Selected to Receive the Mitchell B. Balter Award for Publications in 2025.

Journal of clinical psychopharmacology·2026
Same journal

Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
See all related articles

Physical dependence on triazolam (a benzodiazepine) can occur with high-dose, long-term use. This study describes five cases and outlines a pharmacotherapy approach for managing triazolam withdrawal.

Area of Science:

  • Pharmacology
  • Clinical Psychology
  • Addiction Medicine

Background:

  • Physical dependence to triazolam has not been previously described.
  • High-dose triazolam abuse is a growing concern.
  • Understanding the characteristics of triazolam dependence is crucial for effective treatment.

Purpose of the Study:

  • To describe the clinical characteristics of patients who developed physical dependence to triazolam.
  • To outline a rational pharmacotherapy approach for triazolam withdrawal.
  • To assess the abuse liability of triazolam compared to other benzodiazepines.

Main Methods:

  • Retrospective case series of five patients with high-dose triazolam abuse.
  • Detailed clinical data collection on dosage, duration, and co-occurring conditions.

Related Experiment Videos

  • Pharmacological strategies for triazolam withdrawal management were described.

    • Main Results:

    • Five cases of high-dose triazolam abuse (5-15 mg daily) over 3 months to 5 years were reported.
    • Dependence was associated with a history of substance abuse, anxiety disorders, or inappropriate use.
    • A treatment protocol involving substitution with a long half-life CNS depressant was discussed.

    Conclusions:

    • Triazolam dependence is a clinical reality, often linked to pre-existing conditions.
    • A structured pharmacotherapy approach can effectively manage triazolam withdrawal.
    • Triazolam's abuse liability may be comparable to or less than other benzodiazepines.